Clostridium difficile infection: A review of current and emerging therapies

Annals of Gastroenterology

Volumn 29, Issue 2, 2016, Pages 147-154

  Ofosu, Andrew ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Clostridium difficile infection; Fecal microbial transplantation; Fidaxomicin; Humanized monoclonal antitoxin antibodies; Toxic megacolon

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; CADAZOLID; CRS 3123; FIDAXOMICIN; IMMUNOGLOBULIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL RADIOGRAPHY; BACTERIAL STRAIN; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON RESECTION; COLONOSCOPY; DISEASE SEVERITY; DONOR SELECTION; DRUG EFFICACY; EPIDEMIC; FECAL MICROBIOTA TRANSPLANTATION; FECES CULTURE; HUMAN; ILEOSTOMY; IMMUNOTHERAPY; INTESTINE FLORA; LABORATORY DIAGNOSIS; MORTALITY; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT INFECTION; REVIEW; SCREENING; SIGMOIDOSCOPY; TOXIC MEGACOLON; UNITED STATES;

EID: 84962367282     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: 10.20524/aog.2016.0006     Document Type: Review

References (85)

1. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: Gastroenterology 2012;143:1179-1187;e1-3.
2. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012;81:1-14.
3. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay Hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-415.
4. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States; 2013. Available at: http://www.cdc.gov/ drugresistance/pdf/ar-threats-2013-508.pdf. Accessed December 15, 2015.
5. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-1084.
6. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-2441.
7. Guastalegname M, Grieco S, Giuliano S, et al. A cluster of fulminant Clostridium difficile colitis in an intensive care unit in Italy. Infection 2014;42:585-589.
8. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011;8:17-26.
9. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta- analysis. J Antimicrob Chemother 2014;69:881-891.
10. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013;57:2326‑2332.
11. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013;68:1951-1961.
12. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics J Antimicrob Chemother 2012;67:742-748.
13. Chitnis AS, Holzbauer SM, Belflower RM, et al. Epidemiology of community associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013;173:1359-1367.
14. Sun X, Savidge T, Feng H. The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) 2010;2:1848-1880.
15. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-339.
16. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008;359:1932-1940.
17. Burnham C-AD, Carroll KC. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev 2013;26:604-630.
18. Korman TM. Diagnosis and management of Clostridium difficile infection. Semin Respir Crit Care Med 2015;36:31-43.
19. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478-498.
20. Bulusu M, Narayan S, Shetler K, Triadafilopoulos G. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol 2000;95:3137-3141.
21. Hemminger J, Balada-Llasat JM, Raczkowski M, Buckosh M, Pancholi P. Two case reports of Clostridium difficile bacteremia, one with the epidemic NAP-1 strain. Infection 2011;39:371-373.
22. Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20(Suppl 2):1-26.
23. Mönkemüller K, Patasiūte I, Walther F, Peitz U, Fry LC, Malfertheiner P. Pseudomembranous colitis due to Salmonella enterica serotype infantis. Endoscopy 2006;38:546.
24. Kufelnicka AM, Kirn TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. Clin Infect Dis 2011;52:1451-1457.
25. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015;313:398-408.
26. Murad YM, Perez J, Nokhbeh R, et al. Impact of polymerase chain reaction testing on Clostridium difficile infection rates in an acute health care facility. Am J Infect Control 2015;43:383-386.
27. Ash L, Baker ME, O’Malley CM, et al. Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: prevalence and significance of findings. Am J Roentgenol 2006;186:1393-1400.
28. Johal SS, Hammond J, Solomon K, James PD, Mahida YR. Clostridium difficile associated diarrhea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 2004;53:673-677.
29. Brook I. Pseudomembranous colitis in children. J Gastroenterol Hepatol 2005;20:182-186.
30. Goldstein E, Johnson S, Maziade PJ, et al. Pathway to prevention of nosocomial Clostridium difficile infection. Clin Infect Dis 2015;60(Suppl 2): S148-S158.
31. Dubberke ER, Gerding DN. Rationale for hand hygiene recommendations after caring for a patient with Clostridium difficile infection. Soc Healthcare Epidemiol Am 2011. Available at: http://www.shea-online.org/View/ArticleId/109/Rationale-for-Hand-Hygiene-Recommendations-after-Caring-for-a-Patient-with-Clostridium-difficile-Inf.aspx. Accessed 14 December 2015.
32. Friedenberg F, Fernandez A, Kaul V, et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001;44:1176-1180.
33. Carmo J, Marques S, Chapim I, et al. Leaping forward in the treatment of Clostridium difficile infection: Update in 2015. GE J Port Gastrenterol 2015;22:259-267.
34. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection Control and Hospital Epidemiology 2010;31:431.
35. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002;35:690-696.
36. Cornely OA, Nathwani D, Ivanescu C, et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014;69:2892‑2900.
37. Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother 2011;45:1005-1010.
38. Lamontagne F, Labbé AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007;245:267-272.
39. McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007;28:140-145.
40. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769-1775.
41. Kyne L, Warny M, Qamar A, et al. Association between antibody response in toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189-193.
42. Abdelfatah M, Nayfe R, Nijim A, et al. Factors predicting recurrence of Clostridium difficile infection (CDI) in hospitalized patients: retrospective study of more than 2000 patients. J Investig Med 2015;63:747-751.
43. Kamboj M, Khosa P, Kaltsas A, et al. Relapse versus reinfection: surveillance of Clostridium difficile infection. Clin Infect Dis 2011;53:1003-1006.
44. Figueroa I, Johnson S, Sambol SP, Goldstein EJ, Citron DM, Gerding DN. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012;55(Suppl 2):S104-S109.
45. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-431.
46. Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012;55(Suppl 2):S154-S161.
47. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015;372:1539-1548.
48. Bowman KA, Broussard EK, Surawicz CM. Fecal microbiota transplantation: current clinical efficacy and future prospects. Clin Exp Gastroenterol 2015;8:285-291.
49. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010;44:354-360.
50. Drekonja D, Reich J, Gezahegn S, et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med 2015;162:630-638.
51. Trubiano JA, Gardiner B, Kwong JC, et al. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol 2013;25:255-257.
52. Guidance for industry. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ Vaccines/UCM361393.pdf. Accessed December 15, 2015.
53. Bakken JS, Borody T, Brandt LJ, et al; Fecal Micro-biota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9:1044-1049.
54. Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection 2012;40:643-648.
55. Rohike F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol 2012;5:403-420.
56. Hamilton M, Weingarden A, Sadowsky M, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012;107:761-767.
57. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014;312:1772-1778.
58. Fecal transplant pills: Large-scale production begins. Nonprofit stool bank launched by MIT researchers completes first dose-finding study. http://globenewswire.com/news-release/2015/10/28/780862/10154319/en/Fecal-transplant-pills-Large-scale-production-begins.html. Accessed December 19, 2015.
59. Fuentes S, van Nood E, Tims S, et al. Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J 2014;8:1621-1633.
60. Song Y, Garg S, Girotra M, et al. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. Berg G, (ed.) PLoS One 2013;8:e81330.
61. Mattila E, Arkkila P, Mattila PS, et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2013;37:122-128.
62. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48:e41-e46.
63. Rea MC, Clayton E, O’Connor PM, et al. Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol 2007;56(Pt 7):940-946.
64. Banerjee P, Merkel GJ, Bhunia AK. Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathog 2009;1:8.
65. Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001;69:2762-2765.
66. Tuohy KM, Probert HM, Smejkal CW, Gibson GR. Using probiotics and prebiotics to improve gut health. Drug Discov Today 2003;8:692-700.
67. Edwards-Ingram L, Gitsham P, Burton N, et al. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol 2007;73:2458-2467.
68. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013;382:1249-1257.
69. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-822.
70. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008;1:CD004611.
71. Kreutzer EW, Milligan FD. Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J 1978;143:67-72.
72. Barker RH, Dagher R, Davidson DM, Marquis JK. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther 2006;24:1525-1534.
73. Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:411-420.
74. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 2011;56:19-26.
75. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205.
76. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005;128:764-770.
77. Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C difficile infection: a randomized clinical trial. JAMA 2015;313:1719-1727.
78. Brouwer MS, Roberts AP, Hussain H, Williams RJ, Allan E, Mullany P. Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers. Nat Commun 2013;4:2601.
79. Kali A, Charles MVP, Srirangaraj S. Cadazolid: a new hope in the treatment of Clostridium difficile infection. Australas Med J 2015;8:253-262.
80. Jarrad AM, Karoli T, Blaskovich MAT, Lyras D, Cooper MA. Clostridium difficile drug pipeline: challenges in discovery and development of new agents. J Med Chem 2015;58:5164-5185.
81. Gerding DN, Hecht DW, Louie T, et al. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. J Antimicrob Chemother 2016;71:213-219.
82. Sartelli M, Malangoni MA, Abu-Zidan FM, et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg 2015;10:38.
83. Ferrada P, Velopulos CG, Sultan S, et al. Timing and type of surgical treatment of Clostridium difficile-associated disease: a practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg 2014;76:1484‑1493.
84. Brown CJ, Boutros M, Morris A, Divino CM; CAGS/ACS Evidence Based Reviews in Surgery Group. CAGS and ACS evidence based reviews in surgery. Is a diverting loop ileostomy and colonic lavage an alternative to colectomy for the treatment of severe Clostridium difficile-associated disease? Can J Surg 2014;57:214-216.
85. Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011;254:423-427.